Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

2024-512420-10-00 Protocol 1474-0002 Human pharmacology (Phase I) - Other Ended

Start 9 Mar 2023 · End 25 Feb 2025 · Status Ended · 2 EU/EEA countries · 3 sites · Protocol 1474-0002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 80
Countries 2
Sites 3

Plaque psoriasis

Key facts

Sponsor
Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trial duration
9 Mar 2023 → 25 Feb 2025
Decision date (initial)
2024-10-25
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-512420-10-00
EudraCT number
2021-006280-25
WHO UTN
U1111-1308-0095

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Plaque psoriasis

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Boehringer Ingelheim RCV GmbH & Co. KG

Sponsor organisation
Boehringer Ingelheim RCV GmbH & Co. KG
Address
Dr.-Boehringer-Gasse 5-11, Meidling Meidling
City
Vienna
Postcode
1121
Country
Austria

Locations

2 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 14 1
Romania Ended 17 2
Rest of world
Moldova, Republic of, Georgia
49

Investigational sites

Bulgaria

1 site · Ended
Multispecialty hospital for active treatment Sveta Sofia EOOD
Dermatology and Venereology, Bulevard Bilgariya 104, 1404, Sofiya

Romania

2 sites · Ended
Centrul Medical Monza S.R.L.
2nd and 3rd floors, wards 1, 2, 3, 4, 5, 6, 7, Intrarea Tudor Stefan 38-40, 011658, Bucharest
Spitalul Clinic Judetean De Urgenta Cluj
Ophthalmology Building, 1st floor, wards: 33, 34, 35, Strada Clinicilor 3-5, 400006, Cluj-Napoca

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2023-03-09 2023-05-02 2024-11-20
Romania 2023-03-28 2023-05-09 2024-11-20

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-02 Romania Acceptable
2024-10-23
2024-10-25